Endorectal high-dose-rate brachytherapy boost in rectal cancer: Results of the prospective cohort NOM-3 study on the watch-and-wait strategy.

Abstract

Excellent outcomes were described after using endorectal high-dose-rate (HDR) brachytherapy boost in the non-operative management of rectal cancer. However, evidence regarding this strategy remains limited. The NOM-3 prospective single-centre cohort study aimed to evaluate whether the outcomes of this strategy would match those reported by others. Patients fit for radical surgery with tumours measuring ≤ 5 cm in length and occupying ≤ 50 % of the rectal circumference were eligible. Short-course external beam irradiation and three cycles of FOLFOX4 chemotherapy, followed by a 20 Gy HDR brachytherapy boost in two fractions, were administered. Thirty-two consecutive patients were included. The first tumour response assessment revealed a clinical complete response (cCR) in 34 % of patients, a near-cCR in 44 % and residual tumours in 22 %. Patients with residual tumours underwent R0 surgery. All 25 patients with cCR or near-cCR underwent the watch-and-wait strategy. During a median follow-up of 22 months, eight patients (32 %) experienced regrowth and salvage R0 surgery was performed in seven patients. Non-operative management was achieved in 53 % of the total group and 63 % (17/27) of patients with cT2-T3ab disease. Seven patients had persistent superficial ulceration (all asymptomatic) lasting over a year, with only one experiencing regrowth. Early and late complications were acceptable. HDR brachytherapy boost enabled a high proportion of patients to pursue non-operative management with acceptable toxicity, suggesting its viability as an alternative to surgery. Our findings suggest indefinite surveillance can be adopted in patients with residual superficial mucosal ulceration following HDR brachytherapy.